Circulating XXXX levels during ovulation induction: relation to adiposity and ovarian morphology.

@entity43 @entity1 @entity251 @entity28 @entity1243 @entity53
OBJECTIVE: To assess serum @entity1243 levels based on body habitus and ovarian morphology during controlled @entity43 . DESIGN: Prospective analysis. SETTING: University IVF program. @entity1 (S): @entity1 undergoing IVF-ET were divided into two groups, @entity28 ovulatory @entity1 (n = 6; mean (+/-SD) body mass index, 30.1 +/- 0.6 kg/m(2)) and lean ovulatory @entity1 (n = 20); mean (+/- SD) body mass index 22.0 +/- 0.2 kg/m(2)). Lean @entity1 were categorized further according to whether they had polycystic-appearing ovaries (n = 8) or normal-appearing ovaries (n = 12). INTERVENTION(S): Controlled @entity43 and IVF. MAIN OUTCOME MEASURE(S): Serum @entity53 , @entity251 , and @entity1243 . RESULT(S): Mean (+/- SD) @entity1243 levels were significantly higher before and after GnRH agonist down-regulation in @entity28 @entity1 (41.7 +/- 5.2 pg/mL and 36.1 +/- 5.8 pg/mL, respectively) compared with lean @entity1 (8.4 +/- 1.0 pg/mL and 6.9 +/- 1.1 pg/mL, respectively). Mean (+/- SD) @entity1243 levels increased significantly in both groups (54.5 +/- 5.1 pg/mL and 11.7 +/- 1.2 pg/mL, respectively), and the mean (+/-SD) percentage increase was similar (55% +/- 18% and 54.8% +/- 17%, respectively). Mean (+/-SD) @entity1243 levels were similar in @entity1 with polycystic-appearing and normal-appearing ovaries before controlled @entity43 , but increased significantly in @entity1 with polycystic-appearing ovaries afterward (14.7 +/- 1.8 pg/mL and 9.3 +/- 1.0 pg/mL, respectively). CONCLUSION(S): Significant increases in @entity1243 levels occur during controlled @entity43 , suggesting that @entity1243 plays a role in follicular growth and maturation. The exaggerated response in @entity1 with polycystic-appearing ovaries reflects either a greater number of recruited follicles or a predisposition of adipocytes to @entity1243 production.
